<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580940</url>
  </required_header>
  <id_info>
    <org_study_id>E7160</org_study_id>
    <nct_id>NCT04580940</nct_id>
  </id_info>
  <brief_title>SpyGlass™ Discover Percutaneous</brief_title>
  <official_title>Flexible Percutaneous Transhepatic Cholangiopancreatoscopy (PTCS) in Complex Pancreaticobiliary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To document the clinical utility of percutaneous cholangiopancreatoscopy using a thin,&#xD;
      disposable, flexible endoscope for evaluation and treatment of complex pancreaticobiliary&#xD;
      disease in a prospective, multi-center case series&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This case series aims to illustrate the clinical utility of percutaneous transhepatic&#xD;
      cholangiopancreatoscopy using a thin, disposable, flexible endoscope performed by&#xD;
      gastroenterological endoscopists and/or interventional radiologists in procedures including&#xD;
      but not limited to:&#xD;
&#xD;
        -  PTCS for tissue diagnosis in cases of surgically or pathologically-altered anatomy,&#xD;
&#xD;
        -  PTCS for stone removal after surgically or pathologically-altered anatomy,&#xD;
&#xD;
        -  Percutaneous rendezvous to aid ERCP after failed endoscopic cannulation,&#xD;
&#xD;
        -  Percutaneous delivery of palliative intraluminal brachytherapy,&#xD;
&#xD;
        -  Intra-procedural percutaneous salvage procedures when an initial route of access fails&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Achieving clinical intent of procedure as indicated</measure>
    <time_frame>1 month</time_frame>
    <description>Physicians will report achieving clinical success by recording the completed procedures compared to procedures planned by 30 days (+/- 3 days) after index PTCS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>1 month</time_frame>
    <description>Serious adverse events related to the study device, accessory devices used through the working channel of the SpyGlass™ Discover Digital Catheter or the cholangiopancreatoscopy portion of the PTCS procedure(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>During index procedure</time_frame>
    <description>Rate at which SpyGlass™ Discover digital catheter can be advanced to the target lesion or stone(s) and visualize the target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Time</measure>
    <time_frame>During index procedure</time_frame>
    <description>Time elapsed between first insertion to last removal of the SpyGlass™ Discover digital catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of PTCS procedures</measure>
    <time_frame>1 month</time_frame>
    <description>Number of PTCS procedures required to achieve clinical success until the end of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopist rating</measure>
    <time_frame>During index procedure</time_frame>
    <description>Endoscopist rating of the following attributes when using SpyGlass™ Discover Digital Catheter compared to marketed reusable scopes Ability to complete the procedure Ability to retroflex Ability to selectively advance into targeted ducts Ability to obtain targeted biopsies Ability to grasp stones Ability to guide lithotripsy Ability to suction Ability to irrigate Ability to advance accessories through scope channel Image quality</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pancreatic Diseases</condition>
  <condition>Bile Duct Obstruction</condition>
  <condition>Bile Duct Diseases</condition>
  <arm_group>
    <arm_group_label>Subjects with complex pancreaticobiliary disease</arm_group_label>
    <description>All subjects will undergo the percutaneous transhepatic cholangiopancreatoscopy with the SpyGlass Discover System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SpyGlass™ Discover Digital System</intervention_name>
    <description>Observational, prospective, registry study for the clinical utility of the SpyGlass Discover digital catheter during a PTCS procedure.</description>
    <arm_group_label>Subjects with complex pancreaticobiliary disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with complex pancreaticobiliary disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Scheduled for a percutaneous transhepatic procedure to access the pancreaticobiliary&#xD;
             anatomy that will accommodate passage of SpyGlass™ Discover Digital Catheter per local&#xD;
             standard of practice&#xD;
&#xD;
          2. Written informed consent from patient or legally authorized representative of the&#xD;
             patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication for cholangiopancreatoscopy&#xD;
&#xD;
          2. Subjects with unresolved adverse event(s) associated with prior percutaneous&#xD;
             pancreaticobiliary ductal access&#xD;
&#xD;
          3. &lt;18 years of age&#xD;
&#xD;
          4. Potentially vulnerable subjects, including, but not limited to pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivo Boskoski, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Torsten Beyna, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evangelisches Krakenhaus Düsseldorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehran Fotoohi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Mason</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Blero, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasme University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Lau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prince of Wales Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eran Shlomovitz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto General Hospital, University Health Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohan Ramchandani, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asian Institute of Gastroenterology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo De Moura, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital das Clinicas, Sao Paolo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariano E Gimenez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DAICIM Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monique Barakat, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danielle Vannan, PhD</last_name>
    <phone>1 (774) 249-5711</phone>
    <email>danielle.vannan@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Srey Yin</last_name>
    <phone>1 (978) 364-6366</phone>
    <email>srey.yin@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monique Barakat, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehran Fotoohi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DAICIM Foundation</name>
      <address>
        <city>Caba</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariano Gimenez, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasme University Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Blero, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas</name>
      <address>
        <city>São Paulo</city>
        <zip>05403</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eduardo De Moura, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital, University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eran Shlomovitz, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krakenhaus Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40217</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Torsten Beyna, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <state>NewTerritories</state>
        <zip>999077</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Lau, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asian Institute of Gastroenterology</name>
      <address>
        <city>Hyderabad</city>
        <state>Somajiguda</state>
        <zip>500-082</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohan Ramchandani, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivo Boskoski, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Percutaneous transhepatic cholangiopancreatoscopy</keyword>
  <keyword>spyglass discover</keyword>
  <keyword>pancreaticobiliary disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Diseases</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Bile Duct Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

